Search research articles
Contact Us
Filters
Showing results (141-150 of 160) with videos related to
Page
of 16
Sort By:
Haematologica
|
December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasms
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Naval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Cancer
|
April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors
Koji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
American Journal of Hematology
|
March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia
Koji Sasaki, Hagop Kantarjian, William Wierda, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery
|
March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors
Ahmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Hematology & Oncology
|
October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Musa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
The New England Journal of Medicine
|
May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain, Michael Keating, Philip Thompson, et al.
Cancer
|
August 7, 2025
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia
Jayastu Senapati, Hagop M Kantarjian, Tapan M Kadia, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 160) with videos related to
Sort By:
Page
of 16
Haematologica
|
December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasms
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Naval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Cancer
|
April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors
Koji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
American Journal of Hematology
|
March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia
Koji Sasaki, Hagop Kantarjian, William Wierda, et al.
American Journal of Hematology
|
September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery
|
March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors
Ahmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Hematology & Oncology
|
October 9, 2020
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
Musa Yilmaz, Mansour Alfayez, Courtney D DiNardo, et al.
The New England Journal of Medicine
|
May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain, Michael Keating, Philip Thompson, et al.
Cancer
|
August 7, 2025
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia
Jayastu Senapati, Hagop M Kantarjian, Tapan M Kadia, et al.
Page
of 16